U-SLS

Q:SLS - SELLAS LIFE SCIENCES GROUP INC - Website unknown - click to update

12:27:32 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
SLS - Q	1.2	1.32	·	1.33	0.3	1.3295	-0.0005	0.0	530.7	662	626	1.32 1.3599 1.28	1.914 0.4986	12:06:47	Mar 28	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 626

More trades...

Time ET	Ex	Price	Change	Volume
12:06:47	Q	1.3295	-0.0005	200
12:06:29	Q	1.325	-0.005	100
12:06:29	Q	1.325	-0.005	100
12:06:07	Q	1.33		300
12:06:07	Q	1.33		100
12:06:07	Q	1.33		100
12:06:07	Q	1.33		100
12:06:07	Q	1.33		100
12:06:07	Q	1.33		100
12:06:07	Q	1.33		100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-03-28 16:05	U:SLS	News Release200	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
2024-03-26 07:35	U:SLS	News Release200	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
2024-03-19 16:05	U:SLS	News Release200	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Date ET

Symbol

Type

Headline

2024-03-28 16:05

U:SLS

News Release

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

2024-03-26 07:35

U:SLS

News Release

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

2024-03-19 16:05

U:SLS

News Release

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules